Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Clearmind (CMND) has completed two R&D projects with leading scientists from multiple disciplines at the Hebrew University
  • This was part of a collaboration established with the university’s technology transfer company, Yissum
  • These projects yielded several promising drug candidates that Clearmind and Yissum are now advancing into novel patent applications
  • Clearmind is a psychedelic pharmaceutical biotech company
  • Clearmind Medicine Inc. (CMND) is up 2.74 per cent, trading at C$6.00 per share at 10:34 am ET

Clearmind (CMND) has completed two R&D projects with leading scientists from multiple disciplines at the Hebrew University.

This was part of a collaboration established with the university’s technology transfer company, Yissum. Yissum serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry.

The first project was led by Professor Dmitry Tsvelikhovsky, Professor Masha Niv and Professor Avi Priel. It was designed to investigate and discover innovative synthetic molecules based on known psychedelic chemical motifs. The project included the rational design of novel candidates and in-silico 3D docking studies on the 5HT2A serotonin receptor. It screened the candidates in an in-vitro platform to assess the receptor activation.

The second project was led by Professor Ahmad Masarwa, Professor Avi Priel, and Professor Rami Yaka. It was aimed to synthesize and evaluate the potential therapeutic effect of various chemical psychedelic analogues. The work included alterations of different regions of known molecules to potentially improve their binding capabilities to the 5HT2A receptor. The final stage of this project utilized an animal model to assess a possible increase in safety and efficacy.

These projects yielded several promising drug candidates that Clearmind and Yissum are now advancing into novel patent applications.

Clearmind is a psychedelic pharmaceutical biotech company. Its objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

Clearmind Medicine Inc. (CMND) is up 2.74 per cent, trading at C$6.00 per share at 10:34 am ET.


More From The Market Herald

" @ the Bell: Markets tumble amid rate worries

Canada’s main stock index was weighed down on Monday by commodity-linked and financial stocks. The telecom and utilities sectors posted some gains.
Dolly Varden Silver Corporation - President & CEO, Shawn Khunkhun.

" Dolly Varden Silver (TSXV:DV) reports highest-grade silver assay found so far on the Kitsault Valley Property

Dolly Varden Silver Corporation (DV) discovered the highest-grade silver assay found so far on the Kitsault Valley Property.

" Black Tusk Resources (CSE:TUSK) acquiring PegaLith Project

Black Tusk Resources (TUSK) has signed a $361,000 share purchase agreement to acquire 1396427 BC Ltd.

" Deep South Resources (TSXV:DSM) closes oversubscribed non-brokered private placement

Deep-South Resources (DSM) has closed the final tranche of an oversubscribed, non-brokered private placement for gross proceeds of $490,000.